Ratings Takeda Pharmaceutical Company Limited Nyse

Equities

TAK

US8740602052

Market Closed - Nyse Other stock markets 21:00:02 14/06/2024 BST			5-day change	1st Jan Change
13.1 ^USD	+0.15%		-2.75%	-8.20%

06-14	Takeda Signs Option Agreement with Ascentage to License Leukemia Drug	MT
06-14	Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company's share price in relation to its net book value makes it look relatively cheap.
The company is one of the best yield companies with high dividend expectations.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Analyst opinion has improved significantly over the past four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
With an expected P/E ratio at 46.58 and 64.08 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
TAKEDA PHARMACEUTICAL COMPANY LIMITED	-8.20%	41.3B	-
ELI LILLY AND COMPANY	+50.70%	791B	C+
NOVO NORDISK A/S	+41.96%	630B	B
JOHNSON & JOHNSON	-7.15%	350B	C+
MERCK & CO., INC.	+18.77%	328B	B-
ABBVIE INC.	+8.79%	298B	C+
ASTRAZENECA PLC	+18.02%	246B	B+
ROCHE HOLDING AG	+1.27%	225B	A+
NOVARTIS AG	+11.95%	218B	B-
AMGEN INC.	+3.68%	160B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes